Area of research
Molecular Biology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Prostate Cancer Diagnosis and Treatment, Epigenetics and DNA Methylation, Cancer therapeutics and mechanisms, and Bladder and Urothelial Cancer Treatments.
Patients with multiple mpMRI region of interests: should we omit targeted biopsies of secondary lesions?
Novel ultrasound scoring system to guide cognitive fusion-targeted biopsy: a prospective study
CKS2 promotes the malignant phenotypes of bladder cancer cells via PI3K/AKT signaling pathway activation
Visibility of mpMRI region of interest on ultrasound during cognitive fusion targeted biopsy predicts prostate cancer detection: a prospective single-center study
[A study on the effects of Anti-GM1 on the differentiation and cytotoxic activity of NK cells in nude mice].
PubMed 2024cited by 0position: middle
Potential diagnostic value of multiple indicators combined with total prostate-specific antigen in prostate cancer
Rac Family Small GTPase 3 Correlates with Progression and Poor Prognosis in Bladder Cancer
<p>LncRNA LINC00461 Promotes Colorectal Cancer Progression via miRNA-323b-3p/NFIB Axis</p>
Beneficial effects of combined administration of Clopidogrel and Aspirin on the levels of proinflammatory cytokines, cardiac function, and prognosis in ST-segment elevation myocardial infarction
Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer
Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients
Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer
Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma
Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy
Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer
Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer
Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma
Downregulation of protocadherin-10 expression correlates with malignant behaviour and poor prognosis in human bladder cancer
Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer